- Home
- AMSF vs VALN Comparison
AMSF vs VALN Comparison
Compare AMSF & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMSF | VALN |
|---|---|---|
| Founded | 1985 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 584.3M | 536.9M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AMSF | VALN |
|---|---|---|
| Price | $31.59 | $5.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $46.33 | $15.50 |
| AVG Volume (30 Days) | ★ 202.0K | 31.3K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 8.61% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $317,252,000.00 | N/A |
| Revenue This Year | $8.45 | N/A |
| Revenue Next Year | $6.03 | $93.87 |
| P/E Ratio | $73.95 | ★ N/A |
| Revenue Growth | ★ 2.66 | N/A |
| 52 Week Low | $29.42 | $5.06 |
| 52 Week High | $47.86 | $12.25 |
Technical Indicators
Market Signals| Indicator | AMSF | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 53.95 | 37.25 |
| Support Level | $29.63 | $5.11 |
| Resistance Level | $31.74 | $6.60 |
| Average True Range (ATR) | 0.73 | 0.25 |
| MACD | 0.17 | -0.05 |
| Stochastic Oscillator | 67.09 | 11.13 |
Price Performance
Historical ComparisonAbout AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums. The Company operates as a single reportable segment, Insurance Operations.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.